DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer

Not Applicable

Active, not recruiting

Conditions: Communication
Anxiety
Depression
Coping Skills
Cancer
Hope
Quality of Life

Interventions: Behavioral: Promoting Resilience in Stress Management (PRISM)

First Posted Date: 2018-09-12

Last Posted Date: 2024-12-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 195

Registration Number: NCT03668223

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

and more 2 locations

Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

Phase 2

Active, not recruiting

Conditions: Glioblastoma

Interventions: Drug: Pembrolizumab
Drug: Bevacizumab
Radiation: Re-irradiation

First Posted Date: 2018-09-07

Last Posted Date: 2024-07-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT03661723

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Columbia University / Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 2 locations

Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS

Not Applicable

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Other: Peri-Transfusion QOL Assessment

First Posted Date: 2018-09-06

Last Posted Date: 2024-06-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 62

Registration Number: NCT03660228

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue

Not Applicable

Active, not recruiting

Conditions: Breast Cancer

Interventions: Other: Exercise Intervention

First Posted Date: 2018-09-05

Last Posted Date: 2023-10-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT03657628

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Phase 1

Completed

Conditions: Leukemia
Brain Tumor
Solid Tumor
Lymphoma

Interventions: Drug: ALRN-6924
Drug: Cytarabine

First Posted Date: 2018-08-31

Last Posted Date: 2023-08-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT03654716

Locations: 🇺🇸
UCSF Benioff Children's Hospital, San Francisco, California, United States
🇺🇸
Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Sapacitabine
Drug: Olaparib

First Posted Date: 2018-08-22

Last Posted Date: 2024-03-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT03641755

Locations: 🇺🇸
Broad Institute of MIT, Cambridge, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) Intervention

Not Applicable

Completed

Conditions: Other Cancer

Interventions: Other: Usual Care
Other: PediCARE

First Posted Date: 2018-08-20

Last Posted Date: 2023-05-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT03638453

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA

Phase 1

Active, not recruiting

Conditions: Follicular Lymphoma

Interventions: Drug: Rituximab
Drug: Utomilumab
Drug: PF04518600
Drug: Avelumab

First Posted Date: 2018-08-17

Last Posted Date: 2022-03-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT03636503

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States

and more 3 locations

Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly

Not Applicable

Completed

Conditions: Other Cancer

Interventions: Other: Clinician Communication Skills Training
Other: Advance Care Planning (ACP) Decisions Videos Decisions Aids
Other: Video Declarations (ViDec)

First Posted Date: 2018-08-01

Last Posted Date: 2024-10-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27446

Registration Number: NCT03609177

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Duke Health, Durham, North Carolina, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 1 locations

EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options

Not Applicable

Completed

Conditions: Unresectable Pancreatic Cancer
Metastatic Pancreatic Cancer
Metastatic Colorectal Cancer

Interventions: Behavioral: Chemotherapy education intervention (CEI)
Behavioral: Usual chemotherapy education (CE)

First Posted Date: 2018-07-27

Last Posted Date: 2022-01-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT03602885

Locations: 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

and more 2 locations

Home Terms & Conditions Privacy Policy